Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 7/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6767003 | 0.90 | ALDH1A1 (0.50) | BDKRB1ALDH1A1L3MBTL1KMT2ATDP1 | |
| SCHEMBL6762382 | 0.86 | BDKRB1 (0.44) | BDKRB1ALDH1A1L3MBTL1KMT2AWDR5 | |
| SCHEMBL6764126 | 0.85 | BDKRB1 (0.45) | BDKRB1ALDH1A1L3MBTL1KMT2AWDR5 | |
| SCHEMBL6884912 | 0.84 | MCOLN3 (0.49) | BDKRB1ALDH1A1L3MBTL1KMT2ATDP1 | |
| SCHEMBL6760111 | 0.84 | BDKRB1 (0.46) | BDKRB1ALDH1A1L3MBTL1KMT2AWDR5 | |
| SCHEMBL6762349 | 0.82 | BDKRB1 (0.44) | BDKRB1ALDH1A1L3MBTL1KMT2AWDR5 | |
| SCHEMBL6762828 | 0.81 | ALDH1A1 (0.59) | BDKRB1ALDH1A1L3MBTL1KMT2ATDP1 | |
| SCHEMBL6763299 | 0.81 | BDKRB1 (0.46) | BDKRB1ALDH1A1KMT2A | |
| SCHEMBL6764156 | 0.81 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1KMT2ATDP1POLB | |
| SCHEMBL4032501 | 0.81 | BDKRB1 (0.53) | BDKRB1ALDH1A1L3MBTL1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | LABORATORIES FOURNIER S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
| EP-1351928-A2 | NOVEL N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE | LABORATOIRES FOURNIER S.A. (FR) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002053516-A2 | N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE | LABORATOIRES FOURNIER SA (FR) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | GLS, GLS2, GLRB | BDKRB1 481/4885ALDH1A1 2730/4885L3MBTL1 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.